ROCHE-MO16419



An open-label, randomized phase II study of Herceptin (trastuzumab), Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere (docetaxel), in patients with advanced and/or metastatic breast cancers that overexpress HER2.
trastuzumab
MO16419
HER2-positive metastatic breast cancer
Phase 2
 
July 2015